「Does a third party infringe a patent right by conducting clinical trials on an original drug?」
Practices:Intellectual Property、Patents
Category:Others
Authors | YAMAMOTO, Osamu |
---|---|
Practice Areas | Intellectual Property Patents |
Date of publication | Issue May / June 2021 |
Publication carrying this article | The Patent Lawyer |
Publisher | CTC Legal Media |
Summary
Osamu Yamamoto explains the impact of the recent Intellectual Property High Court decision Reiwa 2 (Ne) 10051, as well as the necessity for reforming the patent system relating to drug marketing approval in Japan.
Other works by YAMAMOTO, Osamu
-
Publications Intellectual Property、Patents Cases
Antibody Patenting – Second Edition –
YAMAMOTO, Osamu
-
Publications Intellectual Property、Patents Laws
Pharmaceutical Test Data Exclusivity
YAMAMOTO, Osamu
-
Publications Intellectual Property、Patents Laws
IP law in Japan : the recent changes
YAMAMOTO, Osamu
-
Publications
2022 – Study Question “Patentability of Diagnostic Methods”
YAMAMOTO, Osamu
-
Publications Intellectual Property、Patents Others
Japanese version of “Amicus Curiae”
YAMAMOTO, Osamu
Other works on Intellectual Property、Patents
-
Publications General Corporate、Intellectual Property
Responsibility of online marketplaces for online infringement of industrial property right
SUEYOSHI, Tsuyoshi
-
Publications Copyright Law、Intellectual Property Laws
Copyrightability of a Computer Program
FUKAI, Toshiyuki
-
Publications Intellectual Property、Patents Laws
Issues of a Use-Limited Invention
FUKAI, Toshiyuki
-
Publications Intellectual Property、Patents Laws
Q&A Practice for Prevention and Treatment of Intellectual Property Troubles “Assertion of abuse of rights against claims based on patent rights
SETO, Kazuki
-
Publications Intellectual Property、Patents Cases
The case with divergent reason for invalidation adopted by the District Court and the High Court (Pitavastatin damage claim case) -Focusing on the support requirement-
TAKAHASHI, Masafumi
Telephone
+81(3)3270-6641